30,13 $
0,10 % gestern
Nasdaq, 28. Oktober, 21:00 Uhr
ISIN
US75382E1091
Symbol
RAPT
Berichte

RAPT Therapeutics Inc Aktie News

Neutral
GlobeNewsWire
ein Tag alt
Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven condition RAPT seeks to develop a differentiated anti-IgE therapy for the many patients with food allergies SOUTH SAN FRANCISCO, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical compa...
Neutral
GlobeNewsWire
7 Tage alt
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the pricing of an underwritten public offering of 8,333,334 shares of it...
Neutral
GlobeNewsWire
7 Tage alt
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that it has commenced an underwritten public offering of shares of its c...
Neutral
Seeking Alpha
8 Tage alt
RAPT Therapeutics, Inc. (NASDAQ:RAPT ) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria October 20, 2025 8:30 AM EDT Company Participants Sylvia Wheeler Brian Wong - CEO, President & Director William Ho - Chief Medical Officer Conference Call Participants Ana Maria Giménez-Arnau Samuel Slutsky - LifeSci Capital, LLC, Research Division Thomas Smith - Leerink Partn...
Positiv
Invezz
9 Tage alt
Biotech stocks are lighting up the tape today, with several clinical-stage companies posting double-digit gains on fresh catalysts. From earnings beats to promising trial data and billion-dollar partnerships, investors are rewarding progress across oncology, immunology, and drug delivery platforms.
Positiv
Investors Business Daily
9 Tage alt
Rapt stock surged Monday after the biotech company said its experimental hives treatment topped Roche's Xolair in a 16-week study.
Neutral
GlobeNewsWire
9 Tage alt
-  RPT904 at both Q8W and Q12W dosing showed comparable efficacy and safety to omalizumab at Q4W dosing-  Efficacy sustained at Week 16 after a single dose of RPT904-  Well tolerated with no serious adverse events related to study drug-  Jeyou to advance RPT904 to Phase 3 development in China-  RAPT to discuss Phase 3 development path with FDA-  RAPT to host conference call at 8:30 am ET today ...
Neutral
GlobeNewsWire
10 Tage alt
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report topline data from the Phase 2 clinical trial of ...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen